Latest Market Capitalization News

Brightstar Resources has secured full funding for its Goldfields Project, targeting 75,000oz gold production annually from mid-2027, while advancing the Sandstone Project towards a potential Tier-1 development with production aimed for 2029.

Genesis Minerals has reported a 29% jump in gold resources to 18.9 million ounces and a 19% rise in reserves to 4.4 million ounces as of December 2025, underpinning its ASPIRE 500 growth strategy with new assets and exploration boosts.

ImpediMed has secured A$15.2 million through a two-tranche placement and share purchase plan, alongside A$5 million in cost reductions, aiming for operating cashflow breakeven by H2 FY28.

Blue Star Helium has completed Stage 1 of its Galactica development, tying six wells into the Pinon Canyon facility and starting spot-priced helium sales. The company raised A$10 million to fund further project expansion and working capital.

BlinkLab has completed onboarding all clinical sites for its pivotal FDA autism trial, enrolled the first participant, and launched a nationwide autism screening program in Morocco. A recent A$17.7 million capital raise will fund further trials and expansion into ADHD diagnostics.

Island Pharmaceuticals has cleared a major regulatory hurdle with the US FDA, confirming a clinical development path for its antiviral Galidesivir under the Animal Rule. Backed by a $9 million capital raise and strategic partnerships, the company is poised for potential US government procurement and biodefence market entry.

NEXTDC has priced and allocated a A$750 million subordinated wholesale notes offer at a floating rate of 3-month BBSW plus 350 basis points, enhancing its liquidity position amid an ambitious A$2.2 billion capital plan.

Auric Mining outlines a bold growth plan centered on Kalgoorlie, targeting 25,000–30,000 ounces of gold production from 2028 with a new processing facility and multiple project acquisitions.

Kelsian Group’s UK arm has clinched a five-year Liverpool bus franchising contract worth $80 million, marking a strategic foothold in the UK’s evolving public transport sector.

Tetratherix Limited has raised approximately $5 million to fast-track its Tutelix prostate spacer into pivotal clinical trials across Australia and the US, aiming to improve radiation therapy for prostate cancer patients.

Acrow Ltd reported a robust 23% revenue increase in 1H FY26, driven by its expanding Industrial Access division, even as net profit fell 22% amid Queensland market softness. The company’s strategic investments and acquisitions position it well for future growth.

Euro Manganese Inc. reported a net loss of $3.6 million for Q3 2025 and extended key financing milestones to June 2026, highlighting ongoing challenges in funding its Chvaletice Manganese Project.